AllergoOncology: Generating a canine anticancer IgE against the epidermal growth factor receptor - 06/09/18
Doi : 10.1016/j.jaci.2018.04.021
Judit Fazekas-Singer, MSc a, b, Josef Singer, MD, PhD a, b, c, Kristina M. Ilieva, MSc d, e, f, Miroslawa Matz, MSc b, Ina Herrmann, DVM a, g, Edzard Spillner, PhD h, Sophia N. Karagiannis, PhD d, e, Erika Jensen-Jarolim, MD a, b 
a Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna, University Vienna, Vienna, Austria
b Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
c Department of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems, Austria
d St John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, London, United Kingdom
e NIHR Biomedical Research Centre at Guy's and St Thomas' Hospital and King's College London, Guy's Hospital, King's College London, London, United Kingdom
f Breast Cancer Now Unit, School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Cancer Centre, London, United Kingdom
g Department for Companion Animals and Horses, Small Animal Clinic, Internal Medicine, University of Veterinary Medicine, Vienna, Austria
h Immunological Engineering, Department of Engineering, Aarhus University, Aarhus, Denmark
| This work was supported by the Austrian Science Fund (FWF) grants P23398-B11, W1205-B09, and SFB F4606-B28. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' National Health Service Foundation Trust and King's College London (grant no. IS-BRC-1215-20006). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. The authors acknowledge support by Breast Cancer Now (147) working in partnership with Walk the Walk; the Medical Research Council (grant no. MR/L023091/1); Cancer Research UK (grant nos. C30122/A11527 and C30122/A15774); and CR UK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre (grant no. C10355/A15587). |
|
| Disclosure of potential conflict of interest: J. Fazekas-Singer, J. Singer, and E. Jensen-Jarolim are inventors of can225IgG, which is claimed by the University of Veterinary Medicine Vienna, Austria. E. Jensen-Jarolim is founder and shareholder of Biomedical International R+D GmbH and inventor on nonrelated patents in allergen immunotherapy, antitumor vaccines, and biomedical imaging. S. N. Karagiannis is founder and shareholder of IGEM Therapeutics Ltd and coinventor of a patent on IgE antibodies for cancer therapy. J. Singer is coinventor of a nonrelated allergen immunotherapy patent. The rest of the authors declare that they have no relevant conflicts of interest. |
Crown Copyright © 2018
Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 3
P. 973 - septembre 2018 Retour au numéro
Article précédent
- Reference values for peripheral blood lymphocyte subsets of healthy children in China
- Yuan Ding, Lina Zhou, Yu Xia, Wei Wang, Ying Wang, Li Li, Zhongxiang Qi, Linqing Zhong, Jinqiao Sun, Wenjing Tang, Fangfang Liang, Haijuan Xiao, Tao Qin, Ying Luo, Xuezhen Zhao, Zhou Shu, Ying Ru, Rongxin Dai, Hong Wang, Yanping Wang, Yongjie Zhang, Suqian Zhang, Cong Gao, Hongqiang Du, Xuan Zhang, Zhaolong Chen, Xiaochuan Wang, Hongmei Song, Jun Yang, Xiaodong Zhao
- Micro RNAs are required for Langerhans cell, skin- and lung-resident macrophage ontogeny
- Yi Yao, Carly Martin, Congcong Yin, Chunyuan Guo, Zheng Dong, Li Zhou, Qing-Sheng Mi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?